Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma

Motzer, R.; Escudier, B.; McDermott, D.; George, S.; Hammers, H.; Srinivas, S.; Tykodi, S.; Sosman, J.; Procopio, G.; Plimack, E.; Castellano, D.; Choueiri, T.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T.; Ueda, Takeshi; Tomita, Y.; Schutz, F.; Kollmannsberger, C.; Larkin, J.; Ravaud, A.; Simon, J.; Xu, Li-an; Waxman, I.; Sharma, Padmanee

doi:10.1056/NEJMoa1510665

Public

Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma

Shared by NobleBlocks on Sep 25, 2015 • 12:00 AM UTC

Authors:

R. Motzer

B. Escudier

D. McDermott

Abstract

BACKGROUND Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated encouraging overall survival in uncontrolled studies in previously treated patients with advanced renal cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in renal cell carcinoma ...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!